Autophagy plays a critical role in tumorigenesis, but how autophagy contributes to cancer cells' responses to chemotherapeutics remains controversial. To investigate the roles of autophagy in malignant gliomas, we used CRISPR/CAS9 to knock out the ATG5 gene, which is essential for autophagosome formation, in tumor cells derived from patients with glioblastoma. While ATG5 disruption inhibited autophagy, it did not change the phenotypes of glioma cells and did not alter their sensitivity to temozolomide, an agent used for glioblastoma patient therapy. Screening of an anticancer drug library identified compounds that showed greater efficacy to ATG5-knockout glioma cells compared to control. While several selected compounds, including nigericin and salinomycin, remarkably induced autophagy, potent autophagy inducers by mTOR inhibition did not exhibit the ATG5-dependent cytoprotective effects. Nigericin in combination with ATG5 deficiency synergistically suppressed spheroid formation by glioma cells in a manner mitigated by Ca 2+ chelation or CaMKK inhibition, indicating that, in combination with autophagy inhibition, calcium-mobilizing compounds contribute to efficient anticancer therapeutics. ATG5-knockout cells treated with nigericin showed increased mitochondria-derived reactive oxygen species and apoptosis compared to controls, indicating that autophagy protects glioma cells from mitochondrial reactive oxygen species-mediated damage.
Autophagy plays a critical role in tumorigenesis, but how autophagy contributes to cancer cells' responses to chemotherapeutics remains controversial. To investigate the roles of autophagy in malignant gliomas, we used CRISPR/CAS9 to knock out the ATG5 gene, which is essential for autophagosome formation, in tumor cells derived from patients with glioblastoma. While ATG5 disruption inhibited autophagy, it did not change the phenotypes of glioma cells and did not alter their sensitivity to temozolomide, an agent used for glioblastoma patient therapy. Screening of an anticancer drug library identified compounds that showed greater efficacy to ATG5-knockout glioma cells compared to control. While several selected compounds, including nigericin and salinomycin, remarkably induced autophagy, potent autophagy inducers by mTOR inhibition did not exhibit the ATG5-dependent cytoprotective effects. Nigericin in combination with ATG5 deficiency synergistically suppressed spheroid formation by glioma cells in a manner mitigated by Ca 2+ chelation or CaMKK inhibition, indicating that, in combination with autophagy inhibition, calcium-mobilizing compounds contribute to efficient anticancer therapeutics. ATG5-knockout cells treated with nigericin showed increased mitochondria-derived reactive oxygen species and apoptosis compared to controls, indicating that autophagy protects glioma cells from mitochondrial reactive oxygen species-mediated damage.
Finally, using a patient-derived xenograft model, we demonstrated that chloroquine, a pharmacological autophagy inhibitor, dramatically enhanced the efficacy of compounds selected in this study. Our findings propose a novel therapeutic strategy in which calcium-mobilizing compounds are combined with autophagy inhibitors to treat patients with glioblastoma.
| INTRODUCTION
Autophagy is an intracellular catabolic mechanism that maintains cellular homeostasis by digesting damaged proteins and organelles which could interfere with normal cellular processes. This lysosomemediated degradation of damaged cellular components also generates energy and macromolecule building blocks to support healthy cell growth. Autophagy is initiated by energy exhaustion, such as occurs when ATP or nutrients are limited, and so is an important energy source when nutrients are depleted. Under such conditions, upregulation of the AMP/ATP ratio activates AMPK, which, in turn, inhibits mTORC1, triggering autophagy. Autophagy is also controlled by changes in intracellular Ca 2+ concentration. The Ca 2+ -calmodulin complex activates calcium/calmodulin-dependent protein kinase kinase (CaMKK1/2), which activates AMPK and triggers autophagy. 1, 2 Lysosomal Ca 2+ signaling can activate autophagy through calcineurin. 3 Thus, autophagy is controlled by multiple signals generated by dynamic changes in nutrient levels and/or calcium mobilization.
Glioblastoma (GBM) is the most common high-grade malignant glioma in humans. GBM is categorized as a WHO grade IV astrocytoma, a very aggressive, invasive and destructive brain tumor. 4 Alterations in several signaling pathways are associated with gliomagenesis, including the receptor tyrosine kinase (RTK)/RAS/ phosphatidylinositol 3-phosphate (PI3K) pathway and the p53 and retinoblastoma tumor suppressor pathways, in combination with epigenetic modifiers. 5 Because autophagy is reportedly required for gliomagenesis, 6 chloroquine (CQ), an autophagy inhibitor used as an
antimalarial agent, has been tested as a treatment for high-grade brain tumors. In in vitro and preclinical studies, CQ enhanced the cytotoxicity of temozolomide (TMZ), an alkylating agent clinically used to treat GBM, by inhibiting mitochondrial autophagy in glioma cells. 7 This study also showed that knockdown of the autophagyrelated gene BECN1 or CQ treatment enhanced TMZ-induced cell death through a reactive oxygen species (ROS)-mediated mechanism. 7 However, a different study reported that knockdown of BECN1 or the autophagy-related gene ATG7 prevented the death of GBM cell lines subjected to combined radiation/TMZ treatment. 8 Although there have been several clinical trials of combined TMZ plus CQ therapy for patients with cancer, including patients with GBM, it is not clear whether this approach is effective. Thus, the effects of autophagy and its inhibitors or inducers on cancer treatment are complicated.
In this study, we successfully used CRISPR/CAS9 to disrupt the ATG5 gene and so disable autophagy in glioma cell lines generated from patients with GBM. Unexpectedly, ATG5 deficiency had no effect on the phenotypes of these glioma cells or on their sensitivity to TMZ in vitro or in vivo. We also conducted a chemical compound screening that revealed that ATG5 deficiency can synergize with the activation of Ca 2+ signaling to induce tumor cell death. Finally, we have demonstrated the clinical relevance of our findings by combining nigericin or salinomycin with the autophagy inhibitor CQ to suppress tumor growth in vivo by a patient-derived xenograft mouse model. Our findings may lead to novel therapeutics for patients with GBM.
| MATERIALS AND METHODS

| Cell lines and cell culture
Human glioma cell lines that were derived from 2 patients with GBM and termed TGS01 and TGS04 were established as described previously. 9 An additional 2 human glioma cell lines (KGS01 and KGS03) that were derived from 2 patients with GBM were used in some experiments. Use of these human materials and protocols was approved by the Ethics Committees of Kanazawa University and the University of Tokyo. Cells were cultured as nonadherent spheroids in serum-free NSPC medium containing DMEM/F12 (Wako, Osaka, Japan), B27, GlutaMAX, penicillin and streptomycin (Thermo Fisher Scientific, Waltham, MA, USA), hEGF (10 ng/mL, Sigma-Aldrich, St.
Louis, MO, USA), and hFGF (10 ng/mL, Wako).
For sphere formation assays, single-cell suspensions were prepared using Accutase (STEMCELL Technologies, Vancouver, BC, Canada). Suspensions were filtered through a 40-μm cell strainer (BD Biosciences, San Jose, CA, USA), and cells were cultured for 14 days in NSPC medium containing 1% methylcellulose (Wako), with or without drugs (see below). IC50 values were calculated using Prism 6 software.
| CRISPR/CAS9-mediated ATG5 knockout
The target sequences of gRNA (sgATG5_4) were selected from a genome-wide single-guide RNA library. 10 The forward and reverse oligonucleotides, including the 20-bp target sequence and a BbsI sticky end, were synthesized, annealed, and inserted into the pX330 plasmid digested with BbsI to create the pX330-sgATG5 plasmid.
TGS01 or TGS04 cells were transfected with 2 μg of the pX330-sgATG5 plasmid using the Amaxa Mouse Neural Stem Nucleofector Kit (Lonza, Basel, Switzerland). Gene disruption in clones derived from single cells was confirmed by western blotting (see below). (IBL, Gunma, Japan, 18953; 1:1000).
| Tumor xenografts
| Autophagy flux
The pMRX-IP-GFP-LC3-RFP-LC3ΔG probe, which was kindly provided by Dr Noboru Mizushima (University of Tokyo), 12 was retrovirally transduced into TGS04 WT or TGS04 ATG5-KO cells. For preparation of retrovirus, 293gp cells were transfected with pMRX-IP-GFP-LC3-RFP-LC3ΔG and pVSV-G. Retrovirus-containing supernatants were concentrated by centrifugation at 6000 g for 16 hours.
Transduced cells were treated with drugs as appropriate and dissociated with Accutase as above before flow cytometric analysis to detect GFP.
| Cell viability
Cell viability was assessed using the WST-8 Cell Counting Kit 
| Drug screening
Libraries used for drug screening were the SCADS Inhibitor Kit-1, 
| Statistical analyses
Student's t test was used to compare 2 groups. One-way analysis of variance followed by Bonferroni's post-hoc test was used to compare more than 2 groups. Differences in survival rate were analyzed using the log-rank test. Significance calculations were performed using Prism 6 software: *P < .05; **P < .01; ***P < .001; ****P < .0001.
3 | RESULTS
| Autophagy inhibition due to ATG5 gene disruption does not affect the proliferation, survival or differentiation of glioma cells in vitro or in vivo
To investigate the roles of autophagy in the survival, proliferation and differentiation of glioma cells, we used CRISPR/CAS9 to disrupt the ATG5 gene, which encodes a molecule essential for autophagosome formation, in glioma cell lines (TGS01 and TGS04) derived from 2 patients with GBM. 9 Using spheroid cultures, we successfully obtained several single-cell-derived ATG5-KO clones from each patient cell line.
Western blotting of all ATG5-KO clones confirmed that ATG5
protein had disappeared and that the LC3-I/LC3-II ratio had dramatically increased, as expected ( Figure 1A and Supplementary 
| Autophagy does not affect the therapeutic efficacy of temozolomide
Although it was reported that TMZ induced autophagy in glioma cells, and pharmacological inhibition of autophagy enhanced the sensitivity of glioma cells to TMZ, the effectiveness of this approach in clinical trials is controversial. [15] [16] [17] [18] [19] We subjected WT and ATG5-KO cells to sphere formation assays in the presence of TMZ but unexpectedly found no differences ( Figure 3A ). When we inhibited autophagy in TMZ-treated control cells by adding CQ, only 10 μmol/L CQ suppressed spheroid formation, and lower CQ concentrations did not show any additive or synergistic effects with TMZ ( Figure 3B ). In mice xenografted with WT or ATG5-KO cells, TMZ suppressed tumor growth to the same extent in both sets of recipients (Figure 3C,D) . Thus, a lack of autophagy does not affect TMZ efficacy in vivo.
| Identification of compounds synergizing with autophagy inhibition
To identify other agents that might synergize with autophagy inhibition to reduce GBM cell growth, we subjected WT and ATG5-KO cells other previous studies showed that salinomycin increased mitochondrial membrane potential (ΔΨ), associated with a decrease in cellular ATP levels, 22, 23 we assumed that salinomycin has a similar effect to nigericin. As expected, we found that salinomycin could, indeed, effectively reduce sphere formation by ATG5-KO cells ( Figure 4D ). While several publications have reported that salinomycin suppresses autophagy, 24, 25 others have claimed that it induces autophagy. 22, 25, 26 This controversy may be due to technical differences in the methods used to detect autophagy.
To resolve this question, we used the GFP-LC3-RFP-LC3ΔG
probe to analyze the effects of compounds on autophagy flux. 
| Autophagy protects glioma cells against calcium mobilization
Because A23187 is a potent calcium ionophore, and nigericin elevates cytoplasmic Ca 2+ , 27 we hypothesized that Ca 
| DISCUSSION
The precise roles of autophagy in GBM have been unclear. In a KRAS-driven GBM mouse model, inhibition of autophagy genes reduced tumorigenesis. 6 In another study, NVP-BEZ235 synergized with CQ to induce apoptosis and regression of established human gliomas in mouse flank xenografts. 28 Huang et al (2017) report that MST4, a member of the mammalian sterile20-like serine/threonine kinase (STK) family, is highly expressed in high-grade and mesenchymal GBM and upregulates autophagy by phosphorylating ATG4B, and that autophagy inhibition decreases the self-renewal, proliferation and tumorigenicity of GBM cells. 29 Figure S2) . We concluded that, although several previous publications have demonstrated that TMZ can induce autophagy in some cases, 7, 32, 33 this agent did not induce autophagy in the cells examined in our study. Indeed, the effect of TMZ on autophagy remains controversial. 34 A contributing factor may be that patientderived glioma cells are highly heterogeneous due to their variable genetic aberrations. That being said, it is interesting that the compounds selected in this study, notably nigericin, consistently induced the autophagy of several different patient-derived glioma cells.
Therefore, we believe that our findings may be very valuable in 39, 40 Conventional autophagy is also involved in mitophagy in a Parkinindependent and ATG5-dependent manner. 41 Accordingly, T lymphocytes from Atg7-KO mice show increased mitochondrial content, ROS production and apoptosis. 42 Liver tumors in Atg5-KO or Atg7-KO mice contain swollen mitochondria and 8-OHdG DNA damage, which is induced by ROS. 43 Mitochondria isolated from Atg7-KO mouse skeletal muscle exhibit defective mitochondrial respiration, and Atg7-KO mouse embryonic fibroblasts show decreased resting mitochondrial oxygen consumption and increased ROS. 44 Taken together, these observations suggest that autophagy controls the number and quality of mitochondria in a cell and, thus, ROS production. Therefore, combining activation of calcium signaling with inactivation of autophagy may efficiently induce tumor cell death.
Although previous studies have reported the existence of a synergistic effect between salinomycin and autophagy inhibition, 22, 26 the exact mechanism by which this interaction triggered cell death has not been elucidated. Our data fill this gap by clearly showing that inhibition of Ca 2+ signaling reduces the synergistic effects of our selected compounds plus ATG5 deficiency. Therefore, we believe that our results have made a significant contribution to elucidating the molecular mechanism by which autophagy supports the survival of glioma cells; that is, autophagy protects glioma cells against the stress caused by Ca 2+ mobilization. In addition, our study has provided important data implicating several drugs that may have novel uses in the treatment of GBM. As there are multiple autophagy inhibitors that are available for use in a clinical setting, including CQ, our findings should accelerate the development of novel therapeutic approaches for the treatment of this disease.
In conclusion, our data support the concept that compounds promoting Ca 2+ mobilization may be combined with autophagy inhibition as a novel therapy for patients with GBM. Further intensive screening of compounds will identify promising candidates as clinically available anticancer drugs in future, and investigation at the molecular level of how autophagy controls mitochondrial functions should reveal new therapeutic targets for this deadly malignancy. 
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